Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 14/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.71 |
| ▸ | GSK3B | P49841 | 7/20 | 0.55 |
| ▸ | CDK2 | P24941 | 5/20 | 0.55 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.55 |
| ▸ | CDC7 | O00311 | 4/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.55 |
| ▸ | PIM1 | P11309 | 4/20 | 0.55 |
| ▸ | PRKACA | P17612 | 4/20 | 0.55 |
| ▸ | HIPK2 | Q9H2X6 | 4/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.55 |
| ▸ | FLT3 | P36888 | 4/20 | 0.54 |
| ▸ | JAK3 | P52333 | 4/20 | 0.54 |
| ▸ | JAK2 | O60674 | 3/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8939672 | 0.86 | ROCK1 (0.72) | ROCK1CYP3A4GSK3BCDK2IRAK4 | |
| SCHEMBL12573266 | 0.84 | ROCK1 (0.69) | ROCK1CYP3A4GSK3BCDK2IRAK4 | |
| SCHEMBL8939679 | 0.83 | CYP3A4 (1.00) | ROCK1CYP3A4GSK3BCDK2IRAK4 | |
| SCHEMBL13887815 | 0.83 | ROCK1 (0.74) | ROCK1CYP3A4GSK3BCDK2IRAK4 | |
| SCHEMBL4484666 | 0.82 | ROCK1 (1.00) | ROCK1CYP3A4GSK3BCDK2IRAK4 | |
| SCHEMBL8939674 | 0.82 | ROCK1 (0.66) | ROCK1CYP3A4GSK3BCDK2IRAK4 | |
| SCHEMBL27821785 | 0.81 | CYP3A4 (0.61) | ROCK1CYP3A4CDK2PRKACACLK4 | |
| SCHEMBL13887921 | 0.80 | ROCK1 (0.71) | ROCK1CYP3A4GSK3BROCK2PRKACA | |
| SCHEMBL4482897 | 0.80 | ROCK1 (0.72) | ROCK1CYP3A4GSK3BPRKACAFLT3 | |
| SCHEMBL1848095 | 0.80 | CDK9 (0.60) | CYP3A4CDK2CLK4FLT3CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2786995-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2311837-B1 | Azaindoles useful as inhibitors of jak and other protein kinases | VERTEX PHARMA (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2332940-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-2311837-A1 | Azaindoles useful as inhibitors of jak and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | ROCK1 333/4885CYP3A4 3152/4885GSK3B 401/4885 |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | ROCK1 333/4885CYP3A4 3152/4885GSK3B 401/4885 |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | LCK, PDXK, CHUK | ROCK1 313/4885CYP3A4 2437/4885GSK3B 444/4885 |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | ROCK1 333/4885CYP3A4 3152/4885GSK3B 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.